You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of New Antibiotics

    SBC: CUBIST PHARMACEUTICALS, INC.            Topic: N/A

    We will develop new antibiotics based on the inhibition of pathogen protein synthesis through a preunexplored mechanism. The aminoacyl tRNA synthetases (AARS), a family of enzymes that catalyze the fprotein translation, will be targeted. The investigators will exploit the significant selectivity shpathogen cells exhibited by lead structures that have been selected for the study. This will providea ...

    SBIR Phase I 1995 Department of Health and Human Services
  2. DEVELOPMENT OF A SCREEN FOR BACTERIAL RNASE P INHIBITORS

    SBC: CUBIST PHARMACEUTICALS, INC.            Topic: N/A

    The need for novel antibiotics has never been greater. Infectious diseases are the third cause of death in the US, and their toll is increasing, with a 580/0 increase in mortality from 1980 to 1992. A large reason for this rise is the evolution and spread of antibiotic- resistant bacteria. We plan to combat this rise in antibiotic resistance by identifying inhibitors of novel bacterial targets to ...

    SBIR Phase I 1997 Department of Health and Human Services
  3. DEVELOPMENT OF A NOVEL TARGET FOR ANTIMICROBIAL DRUG

    SBC: CUBIST PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION: Emergence of antibiotic-resistant microbial pathogens has created a medical crisis. Life-threatening bacterial pathogens, such as Staphylococcus aureus and Entercoccus faecalis, have developed widespread resistance to current antibiotics. Development of new antibiotics has been traditionally based on derivatizing known classes of compounds which target a limited number of cellular pro ...

    SBIR Phase I 1997 Department of Health and Human Services
  4. Inhibiting Pneumocystis Carinii Growth--A New Therapy

    SBC: CUBIST PHARMACEUTICALS, INC.            Topic: N/A

    N/A

    SBIR Phase I 1995 Department of Health and Human Services
  5. Novel Drug Development Strategy for M Tuberculosis

    SBC: CUBIST PHARMACEUTICALS, INC.            Topic: N/A

    N/A

    SBIR Phase I 1995 Department of Health and Human Services
  6. Model Checking for Biomedical Data

    SBC: CYTEL SOFTWARE CORPORATION            Topic: N/A

    We will develop commercial software which implements graphical and numerical methods for checking tadequacy of a variety of regression models frequently used in biomedical studies. In Phase I of theconcentrate on three popular models: the Cox proportional hazards model, the logistic regression modeffects model for longitudinal data. The model checking techniques considered here include the objecpr ...

    SBIR Phase I 1995 Department of Health and Human Services
  7. XENOTRANSPLANTATION AS A TREATMENT FOR LIVER FAILURE

    SBC: Diacrin, Inc.            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  8. SPECT CAMERA FOR MAMMOGRAPHY OF ISOLATED BREAST

    SBC: DIGITAL SCINTIGRAPHICS, INC.            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  9. A2a--Adenosine Agonist for Cardiovascular Imaging

    SBC: Discovery Therapeutics, Inc.            Topic: N/A

    Adenosine produces coronary vasodilation through activation of A-2a adenosine receptors. However adalso acts at A1 adenosine receptors to slow atrioventricular conduction and when injected into man ican be blocked with A1 receptor antagonists. DTI has synthesized a number of adenosine analogs that2a subtype of adenosine receptor and have identified WRC-0470 as a potent selective short acting corou ...

    SBIR Phase I 1995 Department of Health and Human Services
  10. ADENOSINE ANTAGONIST FOR CARDIOPULMONARY RESUSCITATION

    SBC: Discovery Therapeutics, Inc.            Topic: N/A

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
US Flag An Official Website of the United States Government